Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 12/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.35 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4098011 | 0.94 | PDE4B (0.45) | PDE4BCHRM3PIK3CDMAPK1CHRM2 | |
| SCHEMBL4352104 | 0.94 | PDE4B (0.43) | PDE4BCHRM3MAPK1 | |
| SCHEMBL4358179 | 0.94 | PDE4B (0.43) | PDE4BCHRM3PIK3CDMAPK1ROCK2 | |
| SCHEMBL4103839 | 0.93 | PDE4B (0.44) | PDE4BCHRM3CHRM2CHRM1 | |
| SCHEMBL1363424 | 0.93 | PDE4B (0.43) | PDE4BCHRM3PIK3CDMAPK1NR3C1 | |
| SCHEMBL4093692 | 0.93 | PDE4B (0.46) | PDE4BCHRM3PIK3CDMAPK1RPS6KA1 | |
| SCHEMBL4099141 | 0.92 | PDE4B (0.43) | PDE4BCHRM3 | |
| SCHEMBL4087869 | 0.92 | PDE4B (0.46) | PDE4BCHRM3PIK3CDMAPK1RPS6KA1 | |
| SCHEMBL4092315 | 0.92 | PDE4B (0.46) | PDE4BCHRM3PIK3CDMAPK1RPS6KA1 | |
| SCHEMBL4099043 | 0.91 | CHRM3 (0.47) | PDE4BCHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084449-B2 | Dual pharmacophores—PDE4-muscarinic antagonistics | GLAXO GROUP LIMITED (GB) | 2011-12-27 | — | — | US | claimed |
| US-20090203657-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | claimed |
| US-8084449-B2 | Dual pharmacophores—PDE4-muscarinic antagonistics | GLAXO GROUP LIMITED (GB) | 2011-12-27 | — | — | US | disclosed |
| US-20090203657-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203657-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | PDE4A, PDE1A, PDE4B | PDE4B 3/4885CHRM3 8/4885PIK3CD 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.